前列腺癌靶向放射性核素显像剂的研究进展

Research progress of targeted radionuclide imaging agents for prostate cancer

近年来,前列腺癌(prostate cancer,PCa)发病率逐渐上升,正电子发射断层显像(PET)、单光子发射计算机断层显像(SPECT)技术迅速普及,PCa诊断用放射性药物的研究与开发得到了飞速的发展。新型PCa诊断用放射性药物的开发以靶向标记前列腺特异性膜抗原(prostate-specific membrane antigens,PSMA)的药物为主要方向,包括特异性抗体和小分子量抑制剂等。同时也对前列腺癌相关的其他靶点进行了积极地探索,在临床实践中取得了不错的进展。本文就近年来针对前列腺癌特异性分子靶点放射性显像剂的研究进展做一评述。

In recent years,the incidence of prostate cancer(PCa)has gradually increased,positron emission tomography(PET)and single pho-ton emission computed tomography(SPECT)technology have been rapidly popularized,the research and development of radiopharmaceuticals for PCa diagnosis has been developed rapidly.The development of novel radiopharmaceuticals for diagnosing prostate cancer(PCa)primarily focuses on target-ing prostate-specific membrane antigens(PSMA)through drug labeling,including specific antibodies and small molecule inhibitors.At the same time,other targets related to prostate cancer have been actively explored,and good progress has been made in clinical practice.This article reviewed the recent development of radiopharmaceuticals for the diagnosis of specific molecular targets of prostate cancer.